Interlude Plans Phase 3 Trial to Prevent Gluten Injury in Celiac Disease

Interlude Biopharma launched publicly at the International Celiac Disease Symposium in Melbourne, Australia, and announced a Phase 3 trial of larazotide acetate to test whether it can prevent gluten-induced intestinal injury in people with celiac disease. The Miami-based company expects to begin the U.S. study in the first quarter of 2027.

The randomized, double-blind, placebo-controlled study plans to enroll about 414 participants aged 12 to 80 with biopsy-confirmed, well-controlled celiac disease at up to 100 U.S. sites. Participants will receive 0.25 mg or 0.5 mg of larazotide acetate, or placebo, three times daily for 14 weeks.

After a run-in period, participants will eat a study bar containing 500 mg of gluten every other day for four weeks and then daily for eight weeks. The primary endpoint is the proportion of participants who maintain both the structure of the intestinal lining and symptom control, with symptoms assessed using the Celiac Disease Symptom Diary.

Interlude said the FDA recommended testing whether the drug could prevent injury rather than treating patients after gluten exposure had already triggered an immune response. Larazotide acetate is an investigational oral peptide designed to regulate tight junctions in the intestinal barrier by inhibiting zonulin and is being studied as an adjunct to a gluten-free diet.

In an earlier randomized Phase 2b trial involving 342 patients, the 0.5 mg dose met the primary endpoint of reducing celiac disease symptoms in patients following a gluten-free diet. The FDA has granted the candidate Fast Track designation for celiac disease, which currently has no FDA-approved drug treatments.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion